资源 » 技术资源中心 » 抗体资源中心 » Therapeutic Antibody Drug Discovery Planning

Therapeutic Antibody Drug Discovery Planning

What is Involved in Therapeutic Antibody Drug Discovery?

Firstly, target selection is paramount. The characteristics of the intended therapeutic target will define many of the critical decisions of the therapeutic antibody drug discovery process. Key features of the target that necessitate careful consideration and understanding are listed in the table below.

Early Stage Therapeutic Antibody Drug Discovery
-Inform In vivo Studies From In vitro Data

Therapeutic antibody drugs should be well characterized in vitro prior to entering the in vivo phase of investigation. Animal experiments can cost excessive amounts of time and money. Gaining essential measures in vitro will expedite downstream studies through informing dosing regimens, analysis capabilities, and estimating efficacy. Such criteria include:

• Antibody Characterization:
• Dissociation Constant (K_D): Antibody affinity (1/KD) can forecast dosing concentrations.
• Receptor Activating or Blocking Concentrations: Establishing EC50 or IC50 will determine required in vivo concentrations.
• Basic Assays:
• Western Blot to measure denatured protein: Target and effector response is qualified via western blot densitometry.
• Enzyme-linked Immunosorbent Assay (ELISA) with purified protein: Valuable for measuring circulating levels of therapeutic antibody drug.
• Fluorescent Activated Cell Sorting(FACS) to measure fully matured receptor: Realizing in vivo efficacy hinges upon antibodies recognizing endogenous expression states.
• Cell and tissue Immunohistochemistry(IHC) or Immunofluorescence(IF): Visualizing pathological effects of therapy as well as drive new observations to further study.
• Additional Measurements:
• Antibody-dependent Cell-mediated Cytotoxicity or Complement Dependent Cytotoxicity(ADCC/CDC): To a degree, the ability of the antibodies to recruit immune function can be projected by in vitro assays. Properly controlled in vitro ADCC/CDC studies with negative results should give pause to expectation of success in vivo.

Middle Stage Therapeutic Antibody Discovery
-Final Preparations for In vivo Testing

Affinity (1/K_D) may be the most critical characteristic informing the in vitro-in vivo transition. Along with EC50 or IC50, affinity metrics establish the expected range of circulating concentrations required to drive antibody binding, and subsequent effects. Additionally, knowing the performance of a therapeutic antibody drug in typical immunoassays not only validates function but also sets the groundwork for requisite measurements during in vivo testing. Parallel to quantifying antibody binding performance, activation and functional assays gauging therapeutic efficacy should also be firmly established. Some difficulty may arise during transition to in vivo studies as a replete biological system can often muddy results compared to a relatively clean in vitro system. Preparations and practice for in vivo assessment can be made via spiking samples (i.e. serum, tissues) with the antigen or signaling markers intended to be measured. Titration of spiking concentrations in samples will establish the sensitivity of the measurement system. This exercise can test sample processing and help guide modifications to prevent confounding assay results. Every optimization made before commencing in vivo studies means one less hurdle to overcome once precious samples are in hand.

One of the final preparations before entering in vivo studies is to scale up production of therapeutic antibody. Although this stage is downstream in the discovery process, it is a consideration that should be made early in therapeutic antibody drug discovery planning as identical material should be used throughout the study. Different therapeutic antibody technologies lend themselves to varied scales of production. Depending on the final amount of therapeutic antibody needed, hybridoma expansion in flasks, ascites, or roller bottles, phage display, antibody library or some combination of them all may be appropriate.

Late Stage Therapeutic Antibody Drug Discovery
-Beginning In vivo Studies

Once enough therapeutic antibody drug is produced and assays readied, in vivo investigation can commence. In vivo validation will reveal:

Beyond Therapeutic Antibody Drug Discovery
-What to Anticipate

At some point during antibody drug discovery, antibody sequencing should be entertained. Acquiring the sequence of useful antibodies provides significant benefits. Firstly, hybridoma stocks can only survive limited rounds of replication, and even redundant stocks can potentially see catastrophic loss. Sequencing of the antibody preserves the sequence in silico. As the ultimate goal is to generate a therapeutic antibody that can be utilized in man, antibody sequencing also allows for antibody humanization. Humanized antibody can be used in clinical trials and/or further tested in a humanized mouse model to inform safety and efficacy. Additionally, antibody sequencing can allow for lot to lot consistency as well as large scale production needed for expanding studies via recombinant antibody (rAb) technology. Lastly, but certainly not least, antibody sequencing is also required to patent and protect the intellectual property of any potentially novel and useful antibodies.  Although it is possible to arrive at an antibody sequence from traditional hybridoma strategies, ultimately it may be more logical to employ rAb techniques from the start. These are all considerations that need to be evaluated based on budget, time, scope, and technology at your disposal.

Therapeutic Antibody Drug Discovery Related Services

GenScript offers an entire platform of Therapeutic Antibody Drug Discovery Services catering to every step in the process from lead generation, to optimization, and finally production at any scale. A few of our industry leading services include:

• DNA immunization: circumvents in vitro protein antigen production and overcomes difficult targets.
• High Throughput Gene to Antibody: fast and cost effective production of rAb up to 1mg. Ideal for therapeutic antibody drug.
• Anti-idiotype Antibodies: specifically detects antibody drug by targeting just the complementarity determining region.